

# Principles and Mechanisms of Ultrasonic Contrast

Oliver D. Kripfgans

University of Michigan, Dept. Radiology, Ann Arbor, MI

## Educational Objectives


1. Identify the role of contrast agents in enhancing ultrasound image quality
2. Describe implemented imaging techniques of current ultrasound scanners
3. Explain the physics of contrast agents to demonstrate their optimal clinical use

## Clinical background

- Ultrasound scans p.a.: 135 million <sup>(a)</sup>
- 0.5 per cent use contrast enhancing products <sup>(a)</sup>
- Better diagnosis of myocardial perfusion
- Relatively inexpensive imaging technique better diagnostic information.
- **No** FDA approved contrast agent for **radiological** applications

Sources: (a) Amersham Health Inc. owned by GE Healthcare





## Table of Contents

- 1.From B-mode to X-mode
- 2.Physical principles form basis
- 3.Composition of contrast agents
- 4.Mathematical and physical modeling
- 5.Explain imaging modes
- 6.Bioeffects

## From B-mode to X-mode

- Classical Applications
  - B-mode and M-mode
  - Spectral Doppler, Color Flow, and Power Doppler
- New Modes
  - Harmonic imaging
  - Pulse inversion (with harmonic or power mode)
  - Microvascular imaging
  - Flash contrast imaging

## Enhancing Contrast

- Definition of contrast:

$$C = \frac{I_2 - I_1}{I_1}$$


- Role of Ultrasonic Contrast Agents
- Physical principals of Tx, system, and Rx
  - backscatter amplitude
  - creation of none transmit frequencies
  - ... more

## Physical Principals

- Acoustic transmission
  - B-mode, Doppler
- Acoustic bubble response
  - amplitude, phase, frequency, ...
- Frequency - Size relationship
  - Minnaert Frequency: 3  $\mu\text{m}$  gas bubble - 1.1 MHz res freq.

$$f = \frac{1}{2\pi} \frac{1}{R_0} \sqrt{\frac{3 \kappa P_0}{\rho_L}}$$

### Normal reflection



Impedance (Z) :  $Z = \rho \cdot c$

Reflection due to mismatch:  $R = \frac{Z_2 - Z_1}{Z_2 + Z_1}$

Water : 1.5 MRayl, Air : 0.3 MRayl

- Harmonic oscillation  
 $F = kx$
- Equilibrium of imposed pressure

## Rayleigh scatterer

$$\sigma_s = 4\pi a^2 (ka)^4 \left[ \left( \frac{K - K_0}{3K} \right)^2 + \frac{1}{3} \left( \frac{\rho - \rho_0}{2\rho + \rho_0} \right)^2 \right]$$

| Material | Bulk modulus<br>K [MPa] | Density<br>$\rho$ [kg/m <sup>3</sup> ] | Monopole         | Dipole |
|----------|-------------------------|----------------------------------------|------------------|--------|
| Water    | 2250                    | 1000                                   | 0                | 0      |
| Air      | 0.14                    | 1.14                                   | $2.9 \cdot 10^7$ | 0.33   |

## Sonoluminescence

Sonoluminescence is the emission of light by bubbles in a liquid excited by sound. It was first discovered by scientists at the University of Cologne in 1934, but was not considered very interesting at the time. [1]

At least 10,000 degrees Celsius, and possibly a temperature in excess of one million degrees Celsius. [2]




Sources:

1. H. Frenzel and H. Schultes, Z. Phys. Chem. B27, 421 (1934)
2. D. F. Gaitan, L. A. Crum, R. A. Roy, and C. C. Church, J. Acoust. Soc. Am. 91, 3166 (1992)

## Modern Contrast Agents

- 'Gas bubbles'
- Sophisticated shell
  - prevent coalescence, reduce diffusion
  - albumin, lipid, plus receptors, ...
- Complex interior gas
  - low diffusion, low solubility
  - Dodecafluoropentane, others ...




## Modern Contrast Agents

| Manufacturer        | Trade name | Code name          | Interior gas        | Shell material     | Status*               |
|---------------------|------------|--------------------|---------------------|--------------------|-----------------------|
| Acusphere           |            | (AI-700)           | perfluorocarbon     | copolymers         | Phase II              |
| Alliance Pharma.    | Imavist    | (AFO-150)          | perfluorohexane     | surfactant         | Phase II              |
| Andaris Ltd.        | Myomap     | (AIP 201)          | albumin             | air                | suspended             |
| Quantison           |            |                    |                     |                    | suspended             |
| Bracco Diagno.      | SonoVue    | (BR1, BR14)        | perfluorobutane     | phospholipid       | Phase II, (I+)        |
| Byk Gulden          |            | (BY963)            | -                   | phospholipid       | Phase III(E), II      |
| Cavitation Ctrl     | Filmix     | -                  | -                   | lipid              | PreClinical(US), (IE) |
| Tech. ImaRx Pharma. | SonoRx     | -                  | -                   | cellulose          | market(US)            |
| -                   | Definity   | (MRX-115)          | perfluoropropane    | lipid bilayer      | app(E), Phase III/II  |
| -                   |            | (DMP-115)          | air                 | -                  | -                     |
| -                   |            | (YM 454)           | -                   | -                  | Phase III(J)          |
| -                   |            | (MRX-408, MRX-CSI) | perfluoropropane    | -                  | predclinical          |
| Malinckrodt         |            | (MP1550)           | perfluorobutane     | lipid              | predclinical(?)       |
| -                   |            | (MP2211)           | -                   | -                  | -                     |
| Molecular Biosys.   | Oralex     |                    | air                 | dextrose           | Phase II+             |
| -                   | Optison    | (FS069)            | perfluorobutane     | albumin            | market, Phase II      |
| Nycomed             | Sonazoid   | (NC100100)         | perfluorobutane     | lipid              | Phase III/II          |
| POINT Biomedical    | biSphere   | (PB127)            | air                 | gelatine-polymer   | Phase II              |
| Schering AG         | Levovist   | (SHU508A)          | -                   | galactose          | market(E), III+(US/J) |
| -                   | Sonavist   | (SHU563A, SHU616A) | air                 | cyanoacrylate      | Phase II              |
| Sonus Pharma.       | EchoGen    | (QW3600)           | dodecafluoropentane | albumin            | market(E), II/III(US) |
| -                   | SonoGen    | (QW7437)           | -                   | charged surfactant | Phase I               |

\* Status depends on the proposed application

## Mathematical and Physical Modelling

- Equation of motion
- Harmonic response





## Physics of Bubbles

- Energy Balance
  - kinetic and potential energy, Lagrange formalism
  - -> Rayleigh-Plesset equation
  - Ideal gas law, vapor pressure, surface tension (Laplace pressure), viscosity, static pressure, *sound pressure*

$$\partial_t \partial_t R(t) = \frac{1}{R(t)} \left( -\frac{3}{2} (\partial_t R(t))^2 + \frac{1}{\rho_L} \left( \left( p_0 + \frac{2\sigma}{R_0} - p_d \right) \left( \frac{R_0}{R(t)} \right)^{3\gamma} + p_d - \frac{2\sigma}{R(t)} - \frac{4\eta_L \partial_t R(t)}{R(t)} - p_0 - p_{\infty}(t) \right) \right)$$

## Physics of Bubbles


- Energy Balance
  - kinetic and potential energy, Lagrange formalism
  - -> Rayleigh-Plesset equation
  - Ideal gas law, vapor pressure, surface tension (Laplace pressure), viscosity, static pressure, *sound pressure*



## Acoustic Excitation

### • Single Pulse

- one cycle
- increased viscosity
- ring down at resonance frequency of bubble





# Acoustic Excitation


- Continuous Wave Excitation

- ring-up time
- for 4 cycles


- very low pressure
- linear oscillations




0.5 kPa excitation



5 kPa excitation



50 kPa excitation



## The Shelled Bubble

- Elastic Layer based model


- additional parameters:
- mass density of shell material, second surface tension term,
- second viscosity term, elastic modulus of shell material

$$R_1[t] \partial_t U_1[t] \left( 1 + \left( \frac{\rho_L - \rho_S}{\rho_S} \right) \frac{R_1[t]}{R_2[t]} \right) +$$


$$(U_1[t])^2 \left( \frac{3}{2} + \left( \frac{\rho_L - \rho_S}{\rho_S} \right) \left( \frac{4 (R_2[t])^3 - (R_1[t])^3}{2 (R_2[t])^3} \right) \frac{R_1[t]}{R_2[t]} \right) =$$

$$\frac{1}{\rho_S} \left( P_{\infty} \left( \frac{R_{01}}{R_1[t]} \right)^3 x - P_{\infty}[t, \phi] - \frac{2 \sigma_1}{R_1[t]} - \frac{2 \sigma_2}{R_2[t]} - \right.$$


$$\left. 4 \frac{U_1[t]}{R_1[t]} \left( \frac{V_S \mu_S + (R_1[t])^3 \mu_L}{(R_2[t])^3} \right) - 4 \frac{V_S G_S}{(R_2[t])^3} \left( 1 - \frac{R_{01}}{R_1[t]} \right) \right)$$



## Bubble oscillation under $p_{\infty}$ of 150 kPa



## Chaotic oscillation



Source: V Kamath and A Prosperetti, "Numerical integration methods in gas bubble dynamics," J. Acoust. Soc. Am. 85, 1538-1548 (1989)

## Imaging Modes


- Harmonic imaging
- (Harmonic) Coded Excitation
- Pulse inversion & Power pulse inversion
- Flash contrast imaging
- Microvascular imaging
- Agent detection imaging

## Mechanical Index


$$MI = \frac{P_r \text{ [MPa]}}{\sqrt{f \text{ [MHz]}}}$$

Source: CX Deng, Q Xu, RE Apfel, CK Holland "Inertial cavitation produced by pulsed ultrasound in controlled host media", JASA 100 (2) 1199-1208 (1996)


## Harmonic imaging




## Harmonic imaging




## “Activation” of bubble harmonics






## “Activation” of bubble harmonics





## Coded Excitation






Source: A Nowicki, J Litniewski, W Secomski, PA Lewin, I Trots, "Estimation of ultrasonic attenuation in a bone using coded excitation", Ultrasonics (41) 615–621 (2003)







Source: A Nowicki, J Litniewski, W Secomski, PA Lewin, I Trots, "Estimation of ultrasonic attenuation in a bone using coded excitation", Ultrasonics (41) 615–621 (2003)




Source: J Borsboom, CT Chin, N de Jong "Experimental evaluation of a non-linear coded excitation method for contrast imaging" Ultrasonics 42, 671–675 (2004)




## Pulse Inversion


Linear response of tissue





Nonlinear response of a bubble



## Pulse Inversion



## Pulse Inversion




- Hemangioma. Both images with ultrasound contrast agent. (A) conventional imaging (B) Pulse inversion imaging (a)

Source: (a) Averkiou M., Powers J., Skyba D., Bruce M., and Jensen S. "Ultrasound Contrast Imaging Research." *Ultrasound Quarterly* Vol. 19, No. 1, pp. 27-37 (2003)

## Power Pulse Inversion


assume breathing motion of 2 cm/s  
this is: 20  $\mu\text{m}$  per firing, ie. 4.8° phase shift @ 1 MHz

Linear response of tissue




## Power Pulse Inversion

Linear response of (moving) tissue




## Power Pulse Inversion


Nonlinear response of bubbles



## Power Pulse Inversion

Nonlinear response of moving bubbles






- Splenic hemangioma. Both images with ultrasound contrast agent and Power Pulse Inversion. (A) Initial bubbles arrival (B) peripheral filling (a)


Source: (a) Averkiou M., Powers J., Skyba D., Bruce M., and Jensen S. "Ultrasound Contrast Imaging Research." *Ultrasound Quarterly* Vol. 19, No. 1, pp. 27-37 (2003)

## Flash Echo Imaging


Destruction of contrast agents




## Flash Echo Imaging



Source: Chomas JE, et al "Optical observation of contrast agent destruction." *Appl. Phys. Lett.*, Vol. 77, No. 7 (2000)



stable perfusion of the myocardium high MI USCA destruction no agent in myocardium refill of ultrasound contrast agent



Source: (a) Averkiou M., Powers J., Skyba D., Bruce M., and Jensen S. "Ultrasound Contrast Imaging Research." *Ultrasound Quarterly* Vol. 19, No. 1, pp. 27-37 (2003)


## Flash Contrast Imaging



## Microvascular Imaging


- Problem
    - slow velocities
    - few bubbles
    - large tissue scatter
  - Solution
    - Doppler
    - Harmonic
    - Threshold
- Phase wrap to zero

## Microvascular Imaging




Source: M Bruce, M Averkiou, K Tiemann, S Lohmaier, J Powers, K Beach "Vascular flow and perfusion imaging with ultrasound contrast agents" Ultrasound in Med. & Biol., Vol. 30, No. 6, pp. 735-743, 2004

## Microvascular Imaging




Source: M Bruce, M Averkiou, K Tiemann, S Lohmaier, J Powers, K Beach "Vascular flow and perfusion imaging with ultrasound contrast agents" Ultrasound in Med. & Biol., Vol. 30, No. 6, pp. 735-743, 2004

## In vivo Examples



Source: Dr. Fuminori Moriyasu (Department of Gastroenterology & Hepatology, Tokyo Medical University, Japan)




Source: Dr. Fuminori Moriyasu (Department of Gastroenterology & Hepatology, Tokyo Medical University, Japan)



Source: Dr. Fuminori Moriyasu (Department of Gastroenterology & Hepatology, Tokyo Medical University, Japan)




Source: Dr. Fuminori Moriyasu (Department of Gastroenterology & Hepatology, Tokyo Medical University, Japan)




- Breast ductal carcinoma. Both images with ultrasound contrast agent. (A) Single image of a cine-loop (B) microvascular imaging to capture tracks of bubbles.

Source: (a) Averkiou M., Powers J., Skyba D., Bruce M., and Jensen S. "Ultrasound Contrast Imaging Research." *Ultrasound Quarterly* Vol. 19, No. 1, pp. 27-37 (2003)



- Hepatocellular carcinoma. Low mechanical index scanning using SonoVue (Bracco). (A) Early phase arterial blood supply. (B) Complete filling of hepatocellular carcinoma before portal venous enhancement of normal liver (a)

Source: (a) Averkiou M., Powers J., Skyba D., Bruce M., and Jensen S. "Ultrasound Contrast Imaging Research." *Ultrasound Quarterly* Vol. 19, No. 1, pp. 27-37 (2003)




- Agent detection imaging: Levovist (Schering AG)
- Black holes in the images indicate metastases.

Source: (a) Averkiou M., Powers J., Skyba D., Bruce M., and Jensen S. "Ultrasound Contrast Imaging Research." *Ultrasound Quarterly* Vol. 19, No. 1, pp. 27-37 (2003)


## Bioeffects

- Cavitation
  - inertial = transient cavitation bubble collapse (compression phase)
  - theoretical tensile strength: 100 MPa (1.44 nm bubble)
  - experimental values of (hydrophobic particles)
- Contrast agent Levovist




## Mote model

- Levovist
  - suspension of galactose microparticles (99.9%) and
  - palmitic acid (0.1%)



## Collapsing bubble




Source: Lawrence Crum JASA

## *In vivo* Bioeffects

- Observation of:
  - microvascular permeabilization
  - petechial hemorrhage
  - premature ventricular contractions
- Contrast agents:
  - Optison (Mallinckrodt Inc., St. Louis, MO)
  - Definity (Bristol-Myers Squibb Medical Imaging, Inc. N. Billerica, MA)


Source: P. Li, W. Wang, and J. Li, "The impact of cavitation on contrast-enhanced echocardiography on vascular permeability: comparison of three different contrast agents" *Ultrasound in Med. & Biol.*, Vol. 30, No. 1, pp. 83-91 (2004)

## Acoustic pressure



recommended MI: <1 Imagent®, <0.8 Definity®

## Agent Dose



10 to 100 uL/kg Optison®, 6.25 uL/kg Imagent®, 10 to 20 uL/kg Definity®

## Acknowledgments and References

- *In vivo* movies from Dr. Fuminori Moriyasu  
(Department of Gastroenterology & Hepatology, Tokyo Medical University, Japan)
- Illustration movie by ImaRx Therapeutics  
(ImaRx Therapeutics, Inc., Tucson, AZ)
- Some images and illustrations from  
Averkiou M., Powers J., Skiba D., Bruce M., and Jensen S.  
"Ultrasound Contrast Imaging Research." *Ultrasound Quarterly* Vol. 19, No. 1, pp. 27-37 (2003)  
Bruce M., Averkiou M., Tiemann K., Lohmaier S., Powers J., and Beach K. "Vascular Flow and Perfusion Imaging with Ultrasound Contrast Agents." *Ultrasound in Med. & Biol.*, Vol. 30, No. 6, pp. 735-743 (2004)  
T.G. Leighton, *The Acoustic Bubble*, Academic Press (1994)  
Chomas JE et al. "Optical observation of contrast agent destruction." *Appl. Phys. Lett.*, Vol. 77, No. 7 (2000)